Tuspetinib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Tuspetinib comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Leukemia, Myeloid, Acute. Most recent publication: Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia., Cancer Res Commun, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia.
    Sonowal H, Rice WG, Bejar R, et al. · Cancer Res Commun · 2025
    PubMed: PMID 39665627 · NCT03850574 (TUSCANY) · Leukemia, Myeloid, Acute

Publications by year

2025–2025: 1 publications.

2025
1

Publications by indication

Leukemia, Myeloid, Acute (1)

  • Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia.
    Cancer Res Commun · 2025 · PMID 39665627 · NCT03850574

Publications by journal

  • Cancer Res Commun1 paper

All Tuspetinib publications (1)

2025 (1 paper)

  1. Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia.
    Sonowal H, Rice WG, Bejar R, et al. · Cancer Res Commun · 2025 · Derived
    PubMed: PMID 39665627 · NCT03850574 (TUSCANY) · Leukemia, Myeloid, Acute

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Tue, 02 Jun 2026 17:46:42 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).